Daptomycin Injection shortage
To Be Discontinued 2 presentations · 1 manufacturers · first FDA posting 2026-06-30 · last update 2026-06-30
Manufacturers: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | To Be Discontinued | — | Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc. | Posted 06/30/2026 Updated 06/30/2026 Discontinued 06/30/2026 |
| Daptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 06/30/2026 Updated 06/30/2026 Discontinued 06/30/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)